Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (251-260 of 344) with videos related to

Pageof 35
Sort By:
Targeted Oncology|September 22, 2020
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)Naoki Izawa, Kohei Shitara, Kimio Yonesaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2022
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II TrialKensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2021
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical TrialYukihide Kanemitsu, Kohei Shitara, Junki Mizusawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Future Oncology (London, England)|October 18, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancersSara Hurvitz, Matteo Simonelli, Ramón Yarza, et al.
Journal of the National Cancer Institute|October 11, 2013
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysisKoji Oba, Xavier Paoletti, Steven Alberts, et al.
JCO Precision Oncology|January 24, 2025
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 TrialSun Young Rha, Yanqiao Zhang, Anneli Elme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2023
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaSamuel J Klempner, Keun-Wook Lee, Kohei Shitara, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2020
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb studyAkihito Kawazoe, Kensei Yamaguchi, Hisateru Yasui, et al.
Nature Medicine|March 17, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialKohei Shitara, Hirokazu Shoji, Nicola Fazio, et al.
Pageof 35

Showing results (251-260 of 344) with videos related to

Sort By:
Pageof 35
Targeted Oncology|September 22, 2020
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)Naoki Izawa, Kohei Shitara, Kimio Yonesaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2022
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II TrialKensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2021
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical TrialYukihide Kanemitsu, Kohei Shitara, Junki Mizusawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Future Oncology (London, England)|October 18, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancersSara Hurvitz, Matteo Simonelli, Ramón Yarza, et al.
Journal of the National Cancer Institute|October 11, 2013
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysisKoji Oba, Xavier Paoletti, Steven Alberts, et al.
JCO Precision Oncology|January 24, 2025
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 TrialSun Young Rha, Yanqiao Zhang, Anneli Elme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2023
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaSamuel J Klempner, Keun-Wook Lee, Kohei Shitara, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2020
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb studyAkihito Kawazoe, Kensei Yamaguchi, Hisateru Yasui, et al.
Nature Medicine|March 17, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialKohei Shitara, Hirokazu Shoji, Nicola Fazio, et al.
Pageof 35